[{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"Gene and Cell therapies","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sana Biotechnology","amount2":0.69999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.69999999999999996,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Sana Biotechnology \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Sana Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Glial progenitor cell therapy","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Sana Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Sana Biotechnology \/ Sana Biotechnology"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Fujifilm holding","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"iPSC-Derived Cell Therapies","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Sana Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Sana Biotechnology"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CT103A","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sana Biotechnology","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Sana Biotechnology","highestDevelopmentStatusID":"7","companyTruncated":"Sana Biotechnology \/ Sana Biotechnology"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CD22-directed CAR T cell Therapy","moa":"CD22","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Sana Biotechnology \/ National Institutes of Health"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SC451","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SC451","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SG295","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SC291","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SC291","moa":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SC262","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0.13,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Morgan Stanley"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Morgan Stanley"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0.19,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Morgan Stanley"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"UP421","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"SC291","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"SC291","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"UP421","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Sana Biotechnology
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
